Skip to Content

Urovant Sciences Ltd. 

Merger

  • Date:
  • 11/13/2020
  • Company Name:
  • Urovant Sciences Ltd.
  • Stock Symbol:
  • UROV
  • Company Name - Buyer:
  • Sumitovant Biopharma Ltd.
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 11/12/2020

Case Finder

Locate any case using the tools below.

NEW YORK, November 13, 2020 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Urovant Sciences Ltd. (NASDAQ: UROV) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Sumitovant Biopharma Ltd.
 

On November 12, 2020, Urovant announced that it had signed an agreement to be acquired by Sumitovant for approximately $584 million.  Pursuant to the merger agreement, Urovant stockholders will receive $16.25 in cash for each share of Urovant common stock owned.  The deal is scheduled to close in the first quarter of 2021.

Bragar Eagel & Squire is concerned that Urovant’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.  Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Urovant’s stockholders.

The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Urovant Sciences Ltd. . BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: